Chengdu Origen Biotechnology Co., Ltd.
Clinical trials sponsored by Chengdu Origen Biotechnology Co., Ltd., explained in plain language.
-
One shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingThis early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD). The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye injections. Nine participants aged…
Phase: PHASE1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Could a single gene shot replace monthly eye injections for wet AMD?
Disease control OngoingThis early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…
Phase: PHASE1 • Sponsor: Chengdu Origen Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC